In a recent in-depth coverage by GenomeWeb, Aplex Bio’s Hyperplex PCR (hpPCR) technology garnered attention for its ability to revolutionize multiplexed molecular testing by enabling the simultaneous detection of up to 100 targets in a single reaction. The article highlighted how Aplex Bio’s novel approach integrates padlock probes, rolling circle amplification, and nanoparticle-based Nanopixels to achieve high accuracy and sensitivity. This combination allows for an impressive molecular compartmentalization that can isolate and count DNA targets with precision—setting hpPCR apart from conventional methods like digital PCR (dPCR).

The coverage also emphasized the broader implications of this technology for fields such as wastewater epidemiology, forensics, and gene expression analysis. Aplex Bio’s hpPCR not only demonstrates significant technical capabilities but also positions the company as a competitive player in the rapidly growing multiplex PCR market. The analysis underscored Aplex Bio’s strategic focus on high-plex testing for precision medicine and clinical diagnostics, positioning its technology as a potential game-changer for both research and applied sciences.

Read the coverage here: https://www.genomeweb.com/pcr/swedish-startup-aplex-bio-debuts-100-target-hyperplex-pcr